Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06441084 | A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation | not yet recruiting | Phase 1 | 15 | Nuwacell Biotechnologies Co., Ltd.INDUSTRY | 0 | Jun 4, 2024 | clinicaltrials |
| NCT06441097 | Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | not yet recruiting | Phase 2 | 152 | Ruijin HospitalOTHER | 0 | Jun 4, 2024 | clinicaltrials |
| NCT06439173 | Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment | recruiting | — | 40 | Instituto de Investigación Biomédica de SalamancaOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT06440148 | Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis | recruiting | — | 50 | Medical University of LublinOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT06436677 | A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma(AMITY) | recruiting | — | 100 | Peking University First HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT04905810 | Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure | recruiting | Phase 2 | 20 | Brian JonasOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05310591 | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence(CAPTiRALL) | recruiting | Phase 1 / Phase 2 | 26 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05326919 | The Patient Cohort of the National Center for Precision Medicine in Leukemia(eTHEMA) | recruiting | — | 3,000 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05580861 | Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment(SALMA) | recruiting | Phase 1 / Phase 2 | 64 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05868395 | Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma | recruiting | Phase 2 | 16 | Medical University of ViennaOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06225128 | Dynamics of Resistance Emergence to Azacitidine-based Therapies in Acute Myeloid Leukemia(DREAM) | recruiting | — | 120 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06427213 | This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma | not yet recruiting | Phase 2 | 41 | Henan Cancer HospitalOTHER_GOV | 0 | May 23, 2024 | clinicaltrials |
| NCT06299553 | Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) | recruiting | — | 200 | Incyte Biosciences Italy S.r.lINDUSTRY | 1 | May 22, 2024 | clinicaltrials |
| NCT06421805 | Establishing Prospective Mediastinal Tumor Database of PUMCH(MTDPUMCH) | recruiting | — | 2,000 | Peking Union Medical College HospitalOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT05439889 | Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free Remission | recruiting | — | 100 | National Taiwan University HospitalOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06418776 | IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML | recruiting | Phase 3 | 198 | National Research Center for Hematology, RussiaNETWORK | 1 | May 17, 2024 | clinicaltrials |
| NCT06410833 | Belimumab After Rituximab in Resistant Primary Juvenile SS(BRRPJS) | recruiting | Phase 4 | 15 | Peking Union Medical College HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06416267 | Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)(MBL RiskConseq) | not yet recruiting | — | 1,500 | University of HaifaOTHER | 0 | May 16, 2024 | clinicaltrials |
| NCT06416761 | Genetics in the Progression of Nephropathies | recruiting | — | 10,000 | Ospedale San RaffaeleOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT05982275 | Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant(CARTemis-1) | not yet recruiting | Phase 1 / Phase 2 | 25 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06346912 | CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL | recruiting | Early Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT04061512 | Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia(RAINBOW) | recruiting | Phase 2 / Phase 3 | 148 | University College, LondonOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT05950997 | A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL | recruiting | N/A | 89 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06002659 | CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)(CARMA-01) | recruiting | Phase 1 / Phase 2 | 18 | Uppsala UniversityOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06364033 | Biological and Clinical Efficacy of Shingrix in Patients With CLL | not yet recruiting | N/A | 312 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT05502887 | The Endothelial Cell Dysfunction and Outcome Project for Hematological Neoplasms(EndoCDO-H) | recruiting | — | 1,000 | Prof. Dr. Thomas LuftOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT05718986 | Familial B-cell Lymphoproliferative Disorders(Familial_LPD) | not yet recruiting | — | 1,000 | University of HaifaOTHER | 0 | May 8, 2024 | clinicaltrials |
| NCT05869279 | Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia | recruiting | Phase 1 / Phase 2 | 29 | Fondazione Matilde Tettamanti Menotti De Marchi OnlusOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06149910 | Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma | recruiting | — | 450 | All4CureINDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT06218628 | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | recruiting | Phase 1 | 24 | Fox Chase Cancer CenterOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT05879744 | A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) | active not recruiting | Phase 1 | 90 | Cullinan Therapeutics Inc.INDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT06387420 | A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 180 | AkesoINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT06381817 | Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients | recruiting | Phase 3 | 146 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06385808 | Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML | not yet recruiting | N/A | 37 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Apr 26, 2024 | clinicaltrials |
| NCT04142372 | Tissue Microarray of Hematological Malignancies(HemaTMA) | active not recruiting | — | 5,000 | Tampere University HospitalOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT03336931 | PRecISion Medicine for Children With Cancer(PRISM) | active not recruiting | — | 550 | Sydney Children's Hospitals NetworkOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06252298 | A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies | recruiting | Phase 1 | 74 | Sinocelltech Ltd.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT06376214 | Daratumumab for Patients With Light Chain Amyloidosis | recruiting | N/A | 100 | Nanjing University School of MedicineOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06376721 | Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 43 | Beijing Tongren HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06373471 | Improving Quality of Life in Older Patients With Frailty and Hematological Cancer Through Geriatric Assessment(IMPROVE) | recruiting | N/A | 152 | Odense University HospitalOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT03999723 | Combining Active and Passive DNA Hypomethylation(EVI-3) | recruiting | Phase 2 | 196 | Kirsten GrønbækOTHER | 2 | Apr 17, 2024 | clinicaltrials |
| NCT06369935 | A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma. | not yet recruiting | — | 260 | Peking University People's HospitalOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06366802 | Cohort Construction and Prognostic Model Construction for Multiple Myeloma | active not recruiting | — | 1,000 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06367374 | MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL | not yet recruiting | Phase 2 | 66 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Apr 16, 2024 | clinicaltrials |
| NCT06368167 | A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma | not yet recruiting | Phase 2 | 105 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT04793919 | Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia | recruiting | Phase 2 | 89 | Associazione Italiana Ematologia Oncologia PediatricaOTHER | 12 | Apr 15, 2024 | clinicaltrials |
| NCT05791409 | Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL(AETHER) | recruiting | Phase 1 / Phase 2 | 112 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 4 | Apr 12, 2024 | clinicaltrials |
| NCT06359509 | Study of SYS6020 in BCMA-positive Multiple Myeloma | not yet recruiting | Early Phase 1 | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Apr 11, 2024 | clinicaltrials |
| NCT06090786 | Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax | not yet recruiting | N/A | 225 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Apr 10, 2024 | clinicaltrials |
| NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 30 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Apr 10, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2024source: clinicaltrials